WO2026063308A1 - Procédé de test pour le cancer de la vessie - Google Patents

Procédé de test pour le cancer de la vessie

Info

Publication number
WO2026063308A1
WO2026063308A1 PCT/JP2025/031965 JP2025031965W WO2026063308A1 WO 2026063308 A1 WO2026063308 A1 WO 2026063308A1 JP 2025031965 W JP2025031965 W JP 2025031965W WO 2026063308 A1 WO2026063308 A1 WO 2026063308A1
Authority
WO
WIPO (PCT)
Prior art keywords
mutation
seq
bladder cancer
urine
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/JP2025/031965
Other languages
English (en)
Japanese (ja)
Inventor
幸嗣 植田
勇治 箱崎
一真 杉本
春喜 久米
雄太 山田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Japanese Foundation for Cancer Research
University of Tokyo NUC
Original Assignee
Japanese Foundation for Cancer Research
University of Tokyo NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japanese Foundation for Cancer Research, University of Tokyo NUC filed Critical Japanese Foundation for Cancer Research
Publication of WO2026063308A1 publication Critical patent/WO2026063308A1/fr
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Le problème décrit par la présente invention est de développer un nouveau procédé de test permettant le diagnostic non invasif et très précis du cancer de la vessie. La solution selon l'invention porte sur un procédé de test pour le cancer de la vessie à l'aide d'une mutation somatique spécifique du cancer de la vessie en tant que biomarqueur.
PCT/JP2025/031965 2024-09-17 2025-09-10 Procédé de test pour le cancer de la vessie Pending WO2026063308A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2024159803 2024-09-17
JP2024-159803 2024-09-17

Publications (1)

Publication Number Publication Date
WO2026063308A1 true WO2026063308A1 (fr) 2026-03-26

Family

ID=99168346

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2025/031965 Pending WO2026063308A1 (fr) 2024-09-17 2025-09-10 Procédé de test pour le cancer de la vessie

Country Status (1)

Country Link
WO (1) WO2026063308A1 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016536585A (ja) * 2013-11-05 2016-11-24 エージェンシー フォー サイエンス， テクノロジー アンド リサーチ 膀胱癌バイオマーカー
JP2019509487A (ja) * 2016-03-09 2019-04-04 セザンヌ ソシエテ パ アクシオンス シンプリフィエ 膀胱癌のマーカーとしてのクロモグラニンａ
JP2020530980A (ja) * 2017-07-04 2020-11-05 キュアバック アーゲー 新規核酸分子
WO2022030626A1 (fr) * 2020-08-06 2022-02-10 株式会社Ｌｓｉメディエンス Méthode de diagnostic du cancer de la vessie
JP2023527557A (ja) * 2020-05-28 2023-06-29 サイトベイ インコーポレイテッド 細胞病理染色

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016536585A (ja) * 2013-11-05 2016-11-24 エージェンシー フォー サイエンス， テクノロジー アンド リサーチ 膀胱癌バイオマーカー
JP2019509487A (ja) * 2016-03-09 2019-04-04 セザンヌ ソシエテ パ アクシオンス シンプリフィエ 膀胱癌のマーカーとしてのクロモグラニンａ
JP2020530980A (ja) * 2017-07-04 2020-11-05 キュアバック アーゲー 新規核酸分子
JP2023527557A (ja) * 2020-05-28 2023-06-29 サイトベイ インコーポレイテッド 細胞病理染色
WO2022030626A1 (fr) * 2020-08-06 2022-02-10 株式会社Ｌｓｉメディエンス Méthode de diagnostic du cancer de la vessie

Similar Documents

Publication Publication Date Title
JP7285215B2 (ja) 大腸がんを検出するためのバイオマーカー
Chen et al. Elevated level of anterior gradient-2 in pancreatic juice from patients with pre-malignant pancreatic neoplasia
US20190064184A1 (en) Method for the enrichment of cell free nucleosomes
JP2017133831A (ja) 大腸がんの転移検出方法
WO2021045180A1 (fr) Marqueur de cancer gastrique et procédé d'examen l'utilisant
JP2008014937A (ja) 腫瘍マーカー及び癌疾病の罹患の識別方法
KR20190013707A (ko) 암 검출을 위한 뉴클레오솜-전사 인자 복합체의 용도
CN111381042B (zh) 肝细胞癌中大血管侵犯的预测方法、试剂盒及其应用
WO2014183777A1 (fr) Procédés de détection de polypes ou de carcinomes colorectaux et procédés de traitement des polypes ou des carcinomes colorectaux
AU2017260806A1 (en) Markers of endometrial cancer
US20150338412A1 (en) Composition for diagnosis of lung cancer and diagnosis kit for lung cancer
AU2008325187A1 (en) Methods for detecting or monitoring cancer using LPC as a marker
US20090280512A1 (en) Tumor marker for renal cancer and method for determination of occurrence of renal cancer
JP2013245960A (ja) 乳がん患者手術治療後の予後判定方法
WO2026063308A1 (fr) Procédé de test pour le cancer de la vessie
EP2772759B1 (fr) Composition pour diagnostic du cancer des poumons
CN118914553A (zh) 一种结直肠腺瘤和结直肠癌早期筛查的生物标志物的应用
CN117630234A (zh) 良性前列腺增生诊断相关生物标志物及其应用
US20240060979A1 (en) Methods using anti-slc3a2 autoantibodies and slc3a2 for detection of glioma brain tumor from patient serum
TWI845024B (zh) 用以診斷和預斷大腸直腸癌的方法
JP2014020941A (ja) 大腸癌のマーカーおよびそれを用いた診断
EP4685488A1 (fr) Procédé de détection du cancer du rein
CN105102986A (zh) 用于评价前列腺癌进度的分析方法、前列腺癌进度的评价方法、前列腺癌的检测方法以及检查试剂盒
KR20180117918A (ko) Mfap5 측정 제제를 포함하는 대장암 진단용 조성물, 키트, 및 이를 이용한 대장암 진단 방법
Stella Identification of molecular alterations associated with the progression of clear cell Renal Cell Carcinoma by mass spectrometric approaches